Dana Farber ( Dana Farber )

Dana Farber

Dana Farber's picture

Since its founding in 1947, Dana-Farber has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

Dana Farber press release, blog etc

03/07/2018 - 02:20 Dana-Farbers bank of patient-derived tumor xenografts gets major boost from Novartis
03/01/2018 - 09:38 Cognitive decline prevalent among elderly patients with hematologic cancers, study finds
02/22/2018 - 11:21 Dana-Farber Cancer Institute to develop an outpatient hospital satellite at Patriot Place in Foxborough
02/22/2018 - 09:35 Study identifies predictors of immunotherapy response in head and neck cancer
02/21/2018 - 08:16 Dana-Farber Cancer Institute appoints six new members to Board of Trustees
02/12/2018 - 10:35 Study sheds new light on mechanism of breast cancer treatment resistance
01/24/2018 - 00:46 Study provides first systematic survey of metabolites across tumor types
01/11/2018 - 02:50 Discovery suggests new strategy for attacking high-profile but elusive target in cancer
01/09/2018 - 00:17 Due to winter storm Grayson, urgent need for blood and platelets for patients at Dana-Farber and Brigham and Women's Hospital
01/04/2018 - 14:25 Mechanism for resistance to immunotherapy treatment discovered
01/01/2018 - 06:33 Novel diabetes drugs sensitize cancer cells to chemotherapy agents
12/26/2017 - 09:59 Ursula Matulonis, MD, named Brock-Wilson Family Chair
12/19/2017 - 01:52 Backed by Dana-Farber research, FDA approves new indication for a kidney cancer drug
12/11/2017 - 14:37 Study identifies agent that can reverse resistance to targeted drug in some leukemia cell types
12/10/2017 - 14:50 Low-dose treatment with interleukin-2 across multiple studies shows benefits in chronic graft-versus-host disease
12/10/2017 - 14:35 Study shows combining chemotherapy with targeted drug boosts response in chronic lymphocytic leukemia
12/10/2017 - 11:22 Sequencing offers clues to progression toward multiple myeloma
12/10/2017 - 07:21 Rapid Responses, Few Adverse Effects Seen with Targeted Agent in Phase 1 Trial in Rare Blood Disorder